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In the current study, we have further examined the
immunogenicity of HCVE from explanted valves and
valve prostheses using antibodies against endothelial
adhesion molecules. We found that HCVE can express
molecules such as intercellular adhesion molecule–1
(ICAM-1, CD54) or E-selectin (CD62E), which play
critical roles in peripheral blood mononuclear cell
attachment to and arrest on the vascular wall,3,4 an
important step in the initiation of immune responses.
For instance, using a mouse cardiac transplantation
model, Isobe and associates5 demonstrated that inhibi-
tion of CD54 receptor interaction with its ligand, leuko-
cyte function–associated antigen (LFA-1), completely
prevents rejection of the implant and leads to long-term
graft acceptance.
Stimulation of endothelium can lead to its increased
immunogenicity (eg, major histocompatibility complex
[MHC] class II up-regulation) and stimulation of
immune responses in vitro. On cardiac valve prosthe-
ses, this might lead to the removal of the endothelial lin-
ing, subsequently rendering the implant more suscepti-
ble to mechanical stress. To further address the role of
HCVE in the degeneration of biologic heart valve
implants, we analyzed the surface and the internal
structure of such valvular substitutes using immunohis-
tochemistry on cryostat sections of valves and valve
prostheses obtained during replacement operation, rere-
placement or cardiac transplantation, and retransplanta-
A llogeneic heart valves are theoretically ideal forreplacement of any cardiac valve. Advances in the
procurement of allograft heart valve prostheses have
resulted in better availability and viability, thereby
potentially enhancing long-term survival.1 However, the
use of these prostheses is limited, because biologic heart
valve prostheses undergo degeneration after implanta-
tion, which leads to their destruction. The factors caus-
ing this process are not understood, and growing evi-
dence suggests that, besides mechanical stress,
immunogenic properties of the implant (eg, viable
endothelial cells) contribute to the long-term deteriora-
tion. We2 have previously demonstrated the immuno-
genic potential of human cardiac valve endothelium
(HCVE) in vitro.
Objective: For reasons that are still unclear, biologic heart valve prosthe-
ses undergo degeneration after implantation. We studied the possible
role of the immune system in this process. Methods: We examined the
expression of immunologically relevant molecules by human cardiac
valve endothelium in situ and in vitro and studied re-endothelialization
of implanted allogeneic and xenogeneic valvular surfaces using explanted
bioprostheses and valves obtained from donor hearts at cardiac retrans-
plantation. Results: We demonstrate that human cardiac valve endothe-
lial cells express molecules capable of initiating immune responses and
might therefore play a role in the degeneration of viable cardiac valve
prostheses. Also, we show evidence of re-endothelialization on the sur-
faces of xenografts and allografts but not on valves obtained from pre-
viously transplanted hearts. Conclusion: Inasmuch as valves from previ-
ously transplanted hearts seem to be free from degeneration, we
conclude that reduction of the immunogenicity of allograft valve pros-
theses by HLA matching or immunosuppressive treatment might fur-
ther improve long-term results after allograft valve replacement. (J
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tion. We showed that HCVE expresses adhesion mole-
cules such as platelet endothelial cell adhesion mole-
cule (CD31) and human cellular adhesion molecule
(CD44), known to be involved in homing, adhesion,
and migration of immunocompetent cells to tissues as
well as costimulation of T cells via the T-cell reactivi-
ty/costimulatory molecule pathway.6,7 To differentiate
between donor and recipient origin of cells, we used
monoclonal antibodies specific for donor and recipient
MHC class I molecules. We could show a partial re-
endothelialization process on xenoprosthetic and allo-
prosthetic valves of recipient origin after long-term
clinical implantation. In contrast, on surfaces of valves
obtained from previously transplanted hearts, a conflu-
ent layer containing HCVE could be detected showing
no signs of re-endothelialization by the recipient. This
observation is striking, because these valves appear to
be resistant to degeneration, being implanted when fully
viable, without previous cryopreservation, into a recipi-
ent receiving systemic immunosuppression. These find-
ings suggest an important role of the immune system in
the long-term function of allograft valve prostheses and
lead us to the hypothesis that implantation of a fully
viable allograft prosthesis, matched to the HLA pheno-
type of the recipient, might be a way to further improve
long-term results after allograft valve implantation.
Materials and methods
Cell cultures. Valves used for harvesting of endothelial
cells were obtained from patients undergoing elective aortic
valve replacement for valvular insufficiency. HCVE was
obtained by means of a technique previously described2 and
cultured in chamber slide culture chambers, 6- and 96-well
microtiter plates (Nunc A/S, Roskilde, Denmark) at 37°C and
5% carbon dioxide until confluence. Cell cultures were fed by
exchange of medium when necessary. For all experiments,
primary cultures were used as soon as a confluent monolayer
had developed.
Explanted valves. Reference aortic valves (n = 6) were
obtained at the time of replacement for valvular insufficiency
(4/6) and from donor hearts rejected for transplantation (2/6).
Explanted allograft prostheses were obtained at the time of
reoperation for insufficiency and stenosis (n = 12, duration of
implantation 3-12 years, 4 pulmonary frozen homografts
[group A]; 6 aortic frozen homografts [group B], 2 undeter-
mined [group C]). Explanted xenograft prostheses (n = 6, 5
glutaraldehyde-treated stented porcine xenografts, 1 glu-
taraldehyde-treated stented bovine xenograft) were obtained
at the time of second replacement for insufficiency (duration
of implantation 4-12 years). Valves from previously trans-
planted hearts were obtained at the time of retransplantation
or valve replacement (n = 4, duration of implantation 1-4
years). Thus obtained specimens were snap-frozen in liquid
nitrogen, cut into 5 m m sections, and used for immunohisto-
chemical staining.
Aortic endothelium and endocardium. Aortic endotheli-
um and endocardium were obtained at the time of transplan-
tation and cardiectomy for transplantation, both from donors
and recipients or from hearts used for heart valve banking.
Additional endothelial cells were obtained at routine endomy-
ocardial biopsies after cardiac transplantation. The material
was immediately snap-frozen and stored in liquid nitrogen
until further use. Tissue was cut in 5 m m sections and stained
with the use of the panel of antibodies described herein.
HLA phenotypes. Four allograft recipients (2 group A, 2
group B) and all patients undergoing retransplantation under-
went HLA typing to differentiate between potential donor
and recipient cells on the surface of the prostheses. Complete
HLA data were available for 1 valve donor. 
Valve donor:
VD1: HLA-A2 B7,40 BW3,6 Cw3,7 DR2,4(53) DQ3,7
Valve recipients:
VR1:HLA-A1,3 B8,7 Cw7 DR2(15),5(11) DQ1,3(7)
VR2: HLA-A2,9(23) B21(50),12(44) Cw5,6 DR1,7 DQ1(5),2
VR3: HLA-A2,3 B7 (no DR available)
VR4(VD1): HLA-A1,2 B13,7 Cw6 DR6,7
Patients undergoing retransplantation:
rTX1: HLA-A2,26 B60 CW3 DR1,12
rTX2: HLA-A2,30 B39,51 DR1,4
rTX3: HLA-A2,26 B51,60 DR1,6
rTX4: HLA-A2,11 B37,52 Cw2 DR2,1
Donors of original (first) hearts of patients undergoing
retransplantation:
D1(rTX2): HLA-A2 B27,35 Cw2,4 DR1,11
D2(rTX4): HLA-A1,10(26) B8,12 DR,6
Antibodies. All primary antibodies were monoclonal
(mAb). W6/32 (anti–class I heavy chain) was obtained from
American Type Culture Collection (ATCC, Manassas, Va).
Anti-CD29, CD31, CD34, CD44, CD49a, CD49c, CD49d,
CD49e, CD49f, CD51, CD54, CD62P, CD106, anti-H/Y
mAb and anti–factor VIII–related antigen monoclonal anti-
bodies (anti–FVIII–related Ag mAb) were purchased from
Immunotech (Hamburg, Germany). Additional anti–FVIII–
related Ag mAb were purchased from DAKO (Dakopats,
Hamburg, Germany). Anti-CD49b mAb were from Becton
Dickinson (Heidelberg, Germany). Anti-CD62E mAb were
from Dianova (Hamburg, Germany). Anti-CD102 mAb were
from Bender & Co GmbH (Vienna, Austria). Alkaline phos-
phatase anti–alkaline phosphatase (APAAP) and immune
peroxidase (POD) secondary mAb were from DAKO.
Enzyme coupled anti–secondary APAAP mAb were from
Dianova. Primary antibodies used and the primary function
of their corresponding antigens are summarized in Table IA.
Anti-HLA antibodies (see Table IB), which were used to dif-
ferentiate between donor and recipient cells, were kindly pro-
vided by Dr Westphal (Institute of Immunology, Christian
Albrechts Universität Kiel, Kiel, Germany).
Immunohistochemical staining of cells and cryostat sec-
tions. Cells/cryostat sections were fixed in acetone at –20°C
for 10 minutes. Slides were washed 3 times for 2 minutes in
tris-buffered saline solution. The sections and cells adhering
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to the bottom of the culture chambers or wells were incubat-
ed with the primary antibodies for 30 minutes at 37°C in a
humidified atmosphere and stained by means of an APAAP
method or a POD method previously described.2
Results
Characterization of HCVE
HCVE in vitro. Cell morphology was normal for
HCVE, with cells growing to confluent monolayers with-
in the first 4 to 7 days (Fig 1). A detailed description of
HCVE morphology has been published before.2 In brief,
cells were shaped irregularly, showed contact inhibition,
and grew in monolayers without detectable growth pat-
terns. In all cell cultures, characteristic stigmata could be
observed. Fibroblast contamination could be detected
easily by their typical spindle-shaped appearance, their
whorl-like growth, and lack of contact inhibition.
HCVE on valve surfaces. Valves obtained at initial
replacement and from recipient hearts at the time of
transplantation or from beating heart donor organs
rejected for transplantation had intact endothelial lining
(Fig 2, A). Cells grew as a confluent monolayer on the
basal membrane. Valves from explanted first donor
hearts obtained at the time of retransplantation showed
largely or completely intact endothelial lining also, giv-
ing them the same overall appearance as normal valves.
Explanted allograft or xenograft valves showed com-
pletely or largely denuded surfaces. Only tiny areas
could be shown to bear endothelial cells directly adher-
ent to the valve surface. Also, thrombotic material could
be found on the exterior of the prostheses (Fig. 2, B).
Internal structure. A description of the “normal”
morphology of cryostat sections of heart valves has
been given by us and others before.8,9 Basically, valves
obtained at initial replacement or retransplantation
appeared as normal valves with intact endothelial lin-
ing and interior fibroelastic structure in which stromal
cells could be demonstrated (Fig 2, A, and 4).
Allogeneic or xenogeneic valves replaced at rereplace-
ment showed breakup of internal collagenous structure
(Fig 2, B, and 3). The interior of the prostheses showed
areas of calcification and infiltrating cells. No stromal
cells of donor origin could be shown.
Expression of cell surface molecules of HCVE
Reference aortic valves. On microscopic examination,
a continuous monolayer could be detected on the sur-
faces of valves obtained at a primary aortic valve
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Table IA. Antibodies used
Antigen Family Primary antigen function
MHC class I heavy chain HLA (A, B, C) Self/non-self recognition
MHC class II HLA (DR) Restriction of immune response
FVIII-related Ag/vWF Activation of endogenous coagulation
H/Y Blood group antigen
CD29/VLA b 1-chain Integrins b 1 Integrin subunit; forms heterodimer with VLA a -chains, T-cell activation
CD31/PECAM-1 IG supergene Initiation of leukocyte/thrombocyte EC adhesion
CD34 Complementary CAMs Selectin ligand
CD44/ECM R III Cell homing receptor
CD49a/VLA-1 a -chain Integrins a 1 Integrin chain, attachment to and migration through ECM
CD49b/VLA-2 a -chain Integrins a 2 Integrin chain, see CD49a
CD49c/VLA-3 a -chain Integrins a 3 Integrin chain, see CD49a
CD49d/VLA-4 a -chain Integrins a 4 Integrin chain, see CD49a, VCAM-1 (CD106) receptor
CD49e/VLA-5 a -chain Integrins a 5 Integrin chain, see CD49a
CD49f/VLA-6 a -chain Integrins a 6 Integrin chain, see CD49a
CD51/VNR a -chain Integrins Cell-matrix adhesion
CD54/ICAM-1 IG supergene Ligand for LFA-1 and Mac-1, leukocyte adhesion
CD62E/ELAM-1 Selectins Initiation of leukocyte-EC adhesion
CD62P/PADGEM Selectins Initiation of leukocyte-EC adhesion
CD102/ICAM-2 IG supergene Lymphocyte-EC adhesion
CD106/VCAM-1 IG supergene Leukocyte-EC adhesion
FVIII-related Ag/vWF, Factor VIII–related antigen/von Willebrand factor; VLA, very late activation; PECAM-1, platelet endothelial cell adhesion molecule–1; IG,
immunoglobulin; CAMs, cell adhesion molecules; ECM R, extracellular matrix receptor; VCAM-1, vascular cell adhesion molecule–1; VNR, vitronectin receptor;
LFA, leukocyte function–associated antigen; EC, endothelial cell; PADGEM, a -granule membrane protein–140 (P-selectin).
Table IB. Monoclonal antibodies to polymorphic MHC
class I epitopes used for donor/recipient differentiation
Antibody Clone/name31
Anti-HLA-A1 108A6
Anti-HLA-A2 48C1
Anti-HLA-A10 66C4
Anti-HLA-B7 38D4
Anti-HLA-BW6 2BC4
MHC, Major histocompatibility complex; HLA, human leukocyte antigen.
replacement. Immunohistochemical analyses demon-
strated that these cells were positive for the W6/32
(MHC class I), anti-H/Y, CD31, CD34, CD44, CD49a,
CD49c, CD49e, CD49f, CD51, and CD54 antibodies
(Fig 1). This layer stained negatively for FVIII-related
Ag, as we previously reported, and negative for CD49b,
CD49d, CD62E, CD62P, CD102, and CD106 (Table II).
Explanted allograft valves. On 3 allograft valve sur-
faces, cells could be detected that were positive for the
basic antibody panel described earlier as characteristic
of HCVE. They were also positive for FVIII-related Ag
and CD62P (Table II, Fig 3).
Valves from transplanted hearts. On valves from trans-
planted hearts, the observed monolayer was not always
continuous. The endothelial cells showed a similar phe-
notype (Fig 4), although some differences were observed
(Table II). These layers partially stained positive for
FVIII-related Ag also. In addition, cells could be detect-
ed on the surface of those valves that were negative for
H/Y, surprisingly. In contrast to the cell population
described earlier, these cells were positive for CD49b but
negative for CD49f, CD51, and CD54 (Table II).
Explanted xenograft valves. On 2 xenograft valves, a
discontinuous cell lining could be detected directly
adherent to the valve, staining positive for the panel
characteristic for HCVE (Table II) after stimulation
with cytokines. These results confirm previously men-
tioned observations.10 The xenograft valve taken from a
heart at the time of retransplantation was negative for
all antibodies on its surface. It showed a completely
denuded surface. No cell lining could be detected.
Donor-recipient differentiation of cells on valve
surfaces
Explanted allograft valves. With the use of antibod-
ies specific for donor and recipient HLA types, cells of
definite recipient origin could be detected on the sur-
face of 1 of the allograft valves studied. On 2 addition-
al valves, cells could be detected staining only positive
for the recipient panel, while being negative for nonre-
cipient phenotypes. Therefore it is extremely likely that
these cells are of recipient origin.
Valves from transplanted hearts. When donor- and
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Fig 1. HCVE in vitro (APAAP stain, original magnification
· 700). Confluent monolayer of valvular endothelium in in
vitro culture. Cells are stained for MHC class I antigens.
Typical appearance, showing that cells are polygonal and
grow as confluent monolayer without detectable growth pat-
tern. Cell borders are not identifiable. Nuclei are central with
1 to 3 nucleoli.
Fig 2. Cryostat sections. A, Reference aortic valve (APAAP
stain, original magnification · 400). Typical appearance of
endothelial layer on “normal valves” and valves from previ-
ously transplanted hearts. Valve is stained for expression of
CD31 antigens, showing complete endothelial lining.
Expression of CD31 is restricted to the endothelial cells.
Internal tissue was well preserved, showing no signs of calci-
fication or degeneration. B, Explanted allograft valve prosthe-
sis (POD stain, original magnification · 200). Typical appear-
ance of explanted allograft valve, showing denuded surface
and breakup of internal structure.
recipient-specific antibodies were used to differentiate
cells on the surface of valves from transplanted hearts,
no cells could be detected on the valve surface that
were of definite recipient origin. However, infiltration
of cells clearly shown to be of recipient origin could be
demonstrated in the interior of the valves.
Explanted xenograft valves. Because all cells found
on xenograft surfaces must be of recipient origin, no
differentiation was attempted. We could show viable
cells resembling human umbilical vein endothelial cells
on the surface of 2 explants.
Expression of cell surface molecules of aortic
endothelium and endocardium. Aortic endothelium
and endocardium were stained by means of the proto-
col mentioned above. Aortic endothelial cells were pos-
itive for the MHC class I, anti-CD31, CD34, CD44,
CD49a, CD49c, CD49e, CD49f, CD51, and CD54,
which is the same panel of antibodies as HCVE.
However, differences in intensity could be detected. In
contrast to HCVE, aortic endothelium stained negative
for H/Y (Table II). Endothelial cells stained similarly to
aortic endothelial cells but were negative for CD49e,
CD49f, and CD51 (Table II).
HCVE in vitro. Control stains of HCVE in vitro
expressed a panel of molecules identical to that of ref-
erence aortic valve endothelium.
Discussion
The morphology of HCVE in vitro and in vivo has
been described by us and others before. We have previ-
ously shown that HCVE constitutively expresses not
only HLA class I but also class II molecules in vitro and
that MHC-molecule expression on HCVE was marked-
ly increased after stimulation with interferon-g .2 Also,
we reported on the immunogenic properties of HCVE
tested in a mixed lymphocyte endothelial cell culture.2
In the current study, we analyzed the expression of
cell surface molecules known to be involved in rejec-
tion and inflammatory responses. Yacoub11 could not
show MHC class II molecule expression in situ: we
demonstrate such expression not only on the surface of
valves from transplanted hearts, but also on endothe-
lialized portions of explanted prostheses and valves.
The differing expression of class II molecules may be
due to different sensitivities of the mAb used or differ-
ent processing of the valves, but taken together with the
previously described expression in vitro and the
increase after cytokine stimulation, this suggests that
viable HCVE can have an immunostimulatory and sen-
sitizing effect in recipients after allogeneic valve
replacement. 
An initial step in leukocyte-endothelial attachment is
the “rolling” of leukocytes via selectins.4 On valvular
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Table II. Synopsis of immunohistochemical staining of aortic heart valves
Normal Explanted Explanted Valve from 
aortic valve allograft xenograft transplanted heart 
Antibody Normal AE Normal EC endothelium valve valve at re-TX
MHC class I ++ ++ ++ ++ ++ ++
MHC class II ND ND + + + +
FVIII-related Ag - - - ++ + +/-
H/Y - ? ++ ++ ++ ++/-
CD29 ND ND + + ND +
CD31 ++ + ++ ++ ++ ++
CD34 ++ ++ + ND ND -
CD44 ++ ++ ++ ND ND ++
CD49a ++ ++ ++ ND ND ++
CD49b - - - - ND +/-
CD49c ++ ++ ++ ND ND +
CD49d - - - - ND -
CD49e + - ++ + ND -
CD49f + +/- ++ - ND +/-
CD51 + - ++ ND ND +/-
CD54 ++ ++ ++ + + +/-
CD62E* - - - - - +
CD62P - - - + - -
CD102 - -/+ - - - -
CD106 + - - + - -
AE, Aortic endothelium; EC, endothelial cells; Re-TX, Retransplantation; MHC, major histocompatibility complex; FVIII-related Ag, factor VIII–related antigen; ND,
not determined; –, negative; +/–, singular cells, weakly positive; +, positive; ++, strongly positive. Boldface: On the surface of valves from hearts of the first donor,
obtained at the time of retransplantation, cell populations with differences in their expression of surface molecules could be shown.
*CD62E (ELAM-1, endothelial cell leukocyte adhesion molecule) expression has been shown to be inducible.
surfaces from normal valves and nonstimulated cells in
vitro, no expression of E-selectin was observed,
although it has been shown to be inducible in vitro.2 In
rejection or inflammation, leading to CD62E induction
on HCVE, lymphocytes could therefore attach to the
valvular cusps via these fast-acting interactions. Once
host immune cells attach to the endothelial surface,
they become firmly adherent via other adhesive inter-
actions (eg, integrins).12,13 The specificity of this arrest
is assured by expression of homing molecules such as
CD44, CD31, and CD34,7,14,15 which are able to regu-
late the avidity of the leukocyte surface receptors by
“outside-in” signaling. If arrest occurs, the cells can
attack the endothelium, transmigrate through the
endothelial lining, or detach themselves. We have
demonstrated that HCVE expresses homing receptors
such as CD31, CD34, and CD44 and molecules medi-
ating firm adhesion such as CD106, CD102, and CD54
in situ, which enable host leukocytes to attach to the
endothelial lining of a valve prosthesis. In addition,
certain adhesion molecules have been implicated in
providing costimulatory signals.16-18 The observed
expression of stimulatory molecules and adhesion/
costimulatory receptors on HCVE makes the involve-
ment of immunologic processes in the destruction of
valve implants even more probable.
One of the known functions of an endothelial layer is
to sustain the collagenous structures beneath it.19 The
above findings corroborate the hypothesis that deterio-
ration of internal valve structures may be a conse-
quence of de-endothelialization, rendering the valve
susceptible to mechanical stress. Johnson and Fass20
have shown a relative deficiency of fibronectin synthe-
sis by porcine cardiac valvular endothelium in vitro. If
such a deficiency is also to be found in HCVE in vivo,
it could have a significant impact on the reparative
capacity of HCVE on valvular surfaces, leading to a
vicious circle of endothelial and subsequent extracellu-
lar matrix destruction on a valve whose endothelial lin-
ing has been partially destroyed because of its
immunogenic properties.
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Fig 3. Cryostat sections. Immunohistochemical analysis of
sections of explanted aortic valve allograft. A, Leaflet section
stained for CD54 antigens, showing partial re-endothelializa-
tion. A positive monolayer of cells can be detected on the
valvular surface. In other areas of the valve, infiltrating CD54-
positive cells could be demonstrated (not shown). The internal
structure is partially preserved, although breakup and calcifi-
cation could be demonstrated. (APAAP stain, original magni-
fication · 400.) B, Leaflet section stained for CD62P antigens,
showing partial re-endothelialization. A monolayer of cells on
the valvular surface can be detected. Staining is contained to
the valvular surface. (APAAP stain, original magnification
· 100.) C, Leaflet section stained for CD54 antigens, again
showing partial re-endothelialization. As with CD62P, the
staining is contained to the monolayer of cells on the valvular
Fig 4. Cryostat section (APAAP stain, original magnification
· 400). Immunohistochemical staining (anti-CD31) of valve
obtained at time of retransplantation, showing a continuous
monolayer of positive cells on the surface. The internal struc-
ture is well preserved.
Although dendritic cells are thought to play critical
roles in the stimulation of alloimmune responses, its has
been well established that endothelial cells are central to
the stimulation of an alloimmune response too.21-24 It is
not surprising that the immunologic reaction to a par-
tially viable allograft valve is much weaker than the
allogeneic response to a fully viable organ transplant,
which is rejected rapidly and completely destroyed.
However, valves in transplanted hearts showed almost
complete endothelial linings, whereas cryopreserved
allograft valves were almost always completely denuded.
In addition, while the internal structure of an allograft
valve prosthesis seemed largely disrupted, valves
obtained from cardiac transplants had intact internal
structures. An important factor in the lack of degenera-
tion of valves in cardiac transplants may be the
immunosuppression of the recipient, which may lead to
better conservation of HCVE and reduced cell loss on
the valve surface, thus preserving natural repair mecha-
nisms in the valve.
Interestingly, we could detect cells of different pheno-
types (as established by immunohistochemistry) on the
surface of the valves from transplanted hearts. One
appeared to be quite similar to stimulated HCVE on the
basis of H/Y and FVIII-related Ag molecule expression,
although the integrin expression differed. The other
expressed a panel of cell surface molecules that was dif-
ferent from both the first cell type and normal HCVE.
Whereas HCVE expressed an almost identical panel of
surface molecules to aortic endothelium, the panel
expressed by the cell populations found on the valves
from transplanted hearts was closer to that of endocar-
dial cells. Whether this means that the endocardium or
any other cell group, such as the valve endothelium
itself, is able to repopulate the valve surface of a trans-
planted heart, however, remains purely speculative. An
alternative explanation is that the differences in surface
molecule expression are simply the result of different
stages of cell activation and stimulation.
The endothelial marker FVIII-related Ag (von
Willebrand factor), a coagulation factor, seems not to be
expressed by HCVE on normal valves or in a nonstim-
ulated stage in vitro. Once cells are stimulated by inter-
feron-g in vitro or an inflammatory or rejection process-
es in vivo, they do express FVIII-related Ag on their
surface.2 Also, denuded acellular surface areas of valves
stained positive for FVIII-related Ag. These findings
suggest that inflammation, rejection, or loss of the
endothelial lining may increase the thrombogenicity of
the valve surface. Our results are supported by repeated
reports of thrombotic material adherent to the surface of
valves after endocarditis or on biologic valve prostheses
after various durations of implantation in recipients.
Xenograft valves had internal structures that were
comparable with those of explanted allograft valves. It
is unclear how intense and significant the immunolog-
ic reaction of xenograft valve recipients to their pros-
thesis is over the years. However, it is very probable
that mechanical stress plays a major role in the degen-
eration process of this type of biologic heart valve pros-
thesis. Of course, this also suggests that the long-term
degeneration of quickly denuded allograft valves might
be due to a large extent to an increase in sensitivity to
mechanical stress after their immunologic de-endothe-
lialization. In contrast to studies previously published
by other groups, we were able to show a partial re-
endothelialization of xenograft and allograft valve graft
surfaces in vivo. In an earlier study we10 reported on
the presence of HCVE on surfaces of explanted
xenograft valves. The results of the present study cor-
roborate these findings. We could show small HCVE-
bearing areas on the surface of 3 allograft valves. To
our knowledge, we are the first group reporting such re-
endothelialization. Of course, the functional value of
these patches is questionable. On valves of transplanted
hearts, no endothelial cells of recipient origin were
detected. Also, the internal structures of the valves
seemed to be largely intact. However, cells of recipient
origin could be detected in the interior of these valves,
as has been reported by us and others.8,25
The results reported in this study suggest that HCVE
may play an important role in the long-term function of
allograft valve prostheses and that stimulation of a re-
endothelialization process in vivo or in vitro might be
possible. This may limit degeneration due to mechani-
cal stress. Our findings suggest that factors leading to
the destruction of valve allografts may include the
endothelium, which triggers immune response mecha-
nisms in the recipient. This might lead to the loss of the
endothelial lining and a subsequent structural deterio-
ration of the valve matrix resulting from loss of nutri-
ents and increased susceptibility to mechanical stress.
Finally, the stimulation of HCVE and de-endothelial-
ization may increase the valve’s thrombogenicity,
which could also trigger inflammatory processes and
further destroy the prosthetic implant. In this situation,
the implant must finally succumb to the combination of
ongoing mechanical stress and immunologic reaction.
It seems that the implantation of a biologic heart
valve prosthesis, be it a xenogeneic or even a viable
allogeneic one, in essence still results in an early loss
of viability because of uncontrolled immunologic reac-
tions. It is therefore not surprising that the long-term
results after xenograft or allograft valve implantation
are reported to reach comparable plateaus while the
immunologically protected, fully viable aortic valve in
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a cardiac transplant seems to be almost completely
resistant to this degeneration.26 Therefore, since
immunosuppression of valve recipients is not an alter-
native but storage of allograft valves in liquid nitrogen
is possible for any amount of time, HLA-matching of
prospective recipients to their valve could be a feasible
approach toward a solution to this problem. This may
lead to an increase in the long-term survival of allograft
valves after implantation. This hypothesis is corrobo-
rated by the observed superior long-term results in
HLA-matched over mismatched organs (eg, cardiac
transplantations).27-29 In xenografts, reseeding of autol-
ogous endothelial cells to prevent structural degenera-
tion and decrease thrombogenicity may be used to
achieve a similar effect and has already been attempted
in vascular prostheses.30
We thank Drs D. K. C. Cooper and A. N. Warrens for their
careful review of the manuscript.
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